BVF INC/IL
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 98.6%; sector active share 90.8% against the combined 13F book's sector weights.
Over time 26 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
44 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.9% | $3,905,739,213 |
| Financial Services | 0.1% | $5,350,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IVVD | Invivyd, Inc. | +8,640,000 | 28,165,000 | $24,559,880 | |
| — | +5,003,000 | 7,593,303 | $322,715,378 | ||
| OKUR | OnKure Therapeutics, Inc. | +1,256,806 | 3,235,778 | $14,755,147 | |
| AVTX | Avalo Therapeutics, Inc. | +442,700 | 2,075,545 | $38,356,071 | |
| ALKS | Alkermes plc. | +154,704 | 2,154,704 | $112,906,489 | |
| RVMD | Revolution Medicines, Inc. | +108,378 | 2,965,160 | $555,315,164 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IMUX | Immunic, Inc. | −6,887,677 | 765,295 | $11,762,584 | |
| KYMR | Kymera Therapeutics, Inc. | −1,630,658 | 3,872,052 | $444,008,202 | |
| MIRM | Mirum Pharmaceuticals, Inc. | −528,700 | 1,056,027 | $123,629,080 | |
| TYRA | Tyra Biosciences, Inc. | −500,000 | 1,476,196 | $47,149,700 | |
| PVLA | Palvella Therapeutics, Inc. | −288,200 | 672,789 | $102,815,614 | |
| NKTR | Nektar Therapeutics | −168,520 | 2,391,075 | $166,920,945 | |
| IRON | Disc Medicine, Inc. | −118,700 | 1,153,612 | $84,375,181 | |
| GPCR | Structure Therapeutics Inc. | −92,535 | 3,366,823 | $180,697,390 | |
| ZYME | Zymeworks Inc. | −85,000 | 3,649,142 | $95,388,571 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| QTTB | Q32 Bio Inc. | 2,350,000 | $29,939,000 | |
| ABSI | Absci Corp | 2,361,674 | $27,371,801 | |
| SGMT | Sagimet Biosciences Inc. | 2,500,000 | $19,325,000 | |
| RACC | Research Alliance Corp III | 500,000 | $5,350,000 | |
| ENTX | Entera Bio Ltd. | 2,425,000 | $4,292,250 | |
| ENGNW | enGene Therapeutics Inc. | 945,402 | $274,072 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Added | 2,965,160 | $555,315,164 | 14.20% | |
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Reduced | 3,872,052 | $444,008,202 | 11.35% | |
|
|
Added | 7,593,303 | $322,715,378 | 8.25% | ||
| MLTX |
MoonLake Immunotherapeutics
Healthcare
|
Held | 16,001,284 | $311,544,999 | 7.97% | |
| GHRS |
GH Research PLC
Healthcare
|
Held | 8,650,158 | $232,516,247 | 5.95% | |
| GPCR |
Structure Therapeutics Inc.
Healthcare
|
Reduced | 3,366,823 | $180,697,390 | 4.62% | |
| NKTR |
Nektar Therapeutics
Healthcare
|
Reduced | 2,391,075 | $166,920,945 | 4.27% | |
| MIRM |
Mirum Pharmaceuticals, Inc.
Healthcare
|
Reduced | 1,056,027 | $123,629,080 | 3.16% | |
| XNCR |
Xencor Inc
Healthcare
|
Held | 7,133,720 | $114,852,892 | 2.94% | |
| ALKS |
Alkermes plc.
Healthcare
|
Added | 2,154,704 | $112,906,489 | 2.89% | |
| GLUE |
Monte Rosa Therapeutics, Inc.
Healthcare
|
Held | 4,460,886 | $107,953,441 | 2.76% | |
| CGEM |
Cullinan Therapeutics, Inc.
Healthcare
|
Held | 5,750,683 | $104,719,937 | 2.68% | |
| PVLA |
Palvella Therapeutics, Inc.
Healthcare
|
Reduced | 672,789 | $102,815,614 | 2.63% | |
| ZYME |
Zymeworks Inc.
Healthcare
|
Reduced | 3,649,142 | $95,388,571 | 2.44% | |
| KURA |
Kura Oncology, Inc.
Healthcare
|
Held | 8,445,769 | $92,650,085 | 2.37% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
Reduced | 1,153,612 | $84,375,181 | 2.16% | |
| STOK |
Stoke Therapeutics, Inc.
Healthcare
|
Held | 2,547,557 | $83,356,065 | 2.13% | |
| OLMA |
Olema Pharmaceuticals, Inc.
Healthcare
|
Held | 5,295,893 | $66,251,621 | 1.69% | |
| ANNX |
Annexon, Inc.
Healthcare
|
Held | 8,698,173 | $49,666,567 | 1.27% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
Held | 2,748,763 | $49,477,734 | 1.27% | |
| ACIU |
AC Immune SA
Healthcare
|
Held | 19,822,436 | $47,177,397 | 1.21% | |
| TYRA |
Tyra Biosciences, Inc.
Healthcare
|
Reduced | 1,476,196 | $47,149,700 | 1.21% | |
| STRO |
Sutro Biopharma, Inc.
Healthcare
|
Held | 1,251,788 | $41,559,361 | 1.06% | |
| IMCR |
Immunocore Holdings plc
Healthcare
|
Held | 1,294,463 | $41,099,200 | 1.05% | |
| AVTX |
Avalo Therapeutics, Inc.
Healthcare
|
Added | 2,075,545 | $38,356,071 | 0.98% | |
| FDMT |
4D Molecular Therapeutics, Inc.
Healthcare
|
Held | 2,879,289 | $38,294,543 | 0.98% | |
| QTTB |
Q32 Bio Inc.
Healthcare
|
NEW | 2,350,000 | $29,939,000 | 0.77% | |
| AVR |
Anteris Technologies Global Corp.
Healthcare
|
Held | 3,000,000 | $29,550,000 | 0.76% | |
| FHTX |
Foghorn Therapeutics Inc.
Healthcare
|
Held | 5,842,000 | $28,508,960 | 0.73% | |
| ABSI |
Absci Corp
Healthcare
|
NEW | 2,361,674 | $27,371,801 | 0.70% | |
| ELDN |
Eledon Pharmaceuticals, Inc.
Healthcare
|
Held | 6,293,282 | $24,795,531 | 0.63% | |
| IVVD |
Invivyd, Inc.
Healthcare
|
Added | 28,165,000 | $24,559,880 | 0.63% | |
| SGMT |
Sagimet Biosciences Inc.
Healthcare
|
NEW | 2,500,000 | $19,325,000 | 0.49% | |
| OKUR |
OnKure Therapeutics, Inc.
Healthcare
|
Added | 3,235,778 | $14,755,147 | 0.38% | |
| IMUX |
Immunic, Inc.
Healthcare
|
Reduced | 765,295 | $11,762,584 | 0.30% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
Held | 2,233,742 | $10,431,575 | 0.27% | |
| IMA |
ImageneBio, Inc.
Healthcare
|
Held | 1,110,002 | $6,549,011 | 0.17% | |
| TCRX |
TScan Therapeutics, Inc.
Healthcare
|
Held | 5,564,290 | $5,453,004 | 0.14% | |
| RACC |
Research Alliance Corp III
Financial Services
|
NEW | 500,000 | $5,350,000 | 0.14% | |
| MOLN |
Molecular Partners AG
Healthcare
|
Held | 1,353,968 | $5,239,856 | 0.13% | |
| TENX |
Tenax Therapeutics, Inc.
Healthcare
|
Held | 339,549 | $4,940,437 | 0.13% | |
| ENTX |
Entera Bio Ltd.
Healthcare
|
NEW | 2,425,000 | $4,292,250 | 0.11% | |
| IVA |
Inventiva S.A.
Healthcare
|
Held | 686,040 | $2,593,231 | 0.07% | |
| ENGNW |
enGene Therapeutics Inc.
Healthcare
|
NEW | 945,402 | $274,072 | 0.01% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.